权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mouse models of Pik3ca brain overgrowth disorders

Pik3ca 大脑过度生长障碍的小鼠模型

基本信息

批准号：
9905565
负责人：
Kathleen Joyce Millen
金额：
$ 60.5万
依托单位：
SEATTLE CHILDREN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-01 至 2022-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9905565
关键词：
AKT Signaling Pathway Acute Adult Alleles Antiepileptic Agents Antineoplastic Agents Apoptosis Automobile Driving Biological Assay Biological Models Blood capillaries Brain Brain Diseases Brain Pathology CLOVES syndrome Cell Size Cell division Child Chimera organism Cortical Dysplasia Cortical Malformation Data Defect Development Diffuse Dysplasia Disease Dysplasia Electroporation Embryo Enzymes Epidermal nevus Epilepsy Excision Exhibits FRAP1 gene Gene Mutation Germ-Line Mutation Hand Hippocampus (Brain)Hot Spot Hour Human Individual Intellectual functioning disability Intractable Epilepsy Lead Malignant Neoplasms Megalencephaly Modeling Molecular Mosaicism Mus Mutant Strains Mice Mutation Neurons Operative Surgical Procedures PIK3CA gene Pathogenesis Pathway interactions Patients Pharmacology Pharmacotherapy Phenotype Phosphatidylinositols Phosphotransferases Proteomics Proto-Oncogene Proteins c-akt Reporting Reproducibility Resistance Role Seborrheic keratosis Seizures Series Severities Side Signal Pathway Signal Transduction Sirolimus Structural defect Syndrome Technology Testing autism spectrum disorder base blastocyst brain overgrowth cancer type childhood epilepsy clinically relevant critical developmental period developmental disease embryonic stem cell experimental study gain of function gain of function mutation genetic approach hemimegalencephaly human model in utero inhibitor/antagonist mTOR Inhibitor malformation migration mouse model mutant nerve stem cell novel therapeutics pre-clinical standard of care stem cells

项目摘要

PROJECT SUMMARY This proposal outlines a comprehensive series of experiments to assess the basis of overgrowth phenotypes associated with gain of function mutations in PIK3CA, using the mouse as a model system. Although well studied in cancer, recent data has revealed a role for PIK3CA mutation in several developmental disorders including MCAP, DMEG, CLOVES syndrome, epidermal nevi and seborrheic keratosis. Here will assess the developmental and signaling pathway disruptions caused by 3 different Pik3ca gain of function mutations, with particular emphasis on the developing brain. To date, all reported PIK3CA mutations are postzygotic or mosaic rather than germline mutations. Accordingly, we hypothesize that PIK3CA phenotypes correlate with both the severity of the mutation and level (and distribution) of mosaicism. To test this and other hypotheses, we will use standard conditional genetic approaches to express 3 patient-related Pik3ca gof mutations in embryonic CNS neuronal progenitors and their descendants. We will then generate ES cell chimeras, injecting ES cells constitutively expressing the same mutations into wild-type blastocysts to assess phenotype-mosaicism relationships both within the brain and throughout the entire body. We also propose to use in utero electroporation technology to more specifically target mosaic expression to the developing brain. Our studies will assess the developmental pathogenesis of brain pathology and characterize the associated epilepsy, a pressing clinically relevant phenotype. Finally, we will use pharmacological approaches to assess the underlying mechanisms driving acutely Pik3ca-dependent seizures in post-natal mice. These assays represent the first step toward developing molecularly rational epilepsy therapy in PIK3CA segmental brain overgrowth syndrome patients.

项目总结